NO20072712L - Farmasoytisk preparat for behandling av konsekvensene av alkoholmisbruk, hepatitt, pankreatitt, Alzheimer's sykdom, Parkinsons sykdom, toksisk nyresykdom, reperfusjonsskade, arteriosklerose og som en antidote mot miljotoksiner og medikamentforgiftning - Google Patents

Farmasoytisk preparat for behandling av konsekvensene av alkoholmisbruk, hepatitt, pankreatitt, Alzheimer's sykdom, Parkinsons sykdom, toksisk nyresykdom, reperfusjonsskade, arteriosklerose og som en antidote mot miljotoksiner og medikamentforgiftning

Info

Publication number
NO20072712L
NO20072712L NO20072712A NO20072712A NO20072712L NO 20072712 L NO20072712 L NO 20072712L NO 20072712 A NO20072712 A NO 20072712A NO 20072712 A NO20072712 A NO 20072712A NO 20072712 L NO20072712 L NO 20072712L
Authority
NO
Norway
Prior art keywords
disease
hepatitis
antidote
arteriosclerosis
parkinson
Prior art date
Application number
NO20072712A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Haehner
Dieter Mueller-Enoch
Original Assignee
Dieter Mueller-Enoch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dieter Mueller-Enoch filed Critical Dieter Mueller-Enoch
Publication of NO20072712L publication Critical patent/NO20072712L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20072712A 2004-10-29 2007-05-29 Farmasoytisk preparat for behandling av konsekvensene av alkoholmisbruk, hepatitt, pankreatitt, Alzheimer's sykdom, Parkinsons sykdom, toksisk nyresykdom, reperfusjonsskade, arteriosklerose og som en antidote mot miljotoksiner og medikamentforgiftning NO20072712L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004052697A DE102004052697A1 (de) 2004-10-29 2004-10-29 Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation
PCT/DE2005/001938 WO2006045298A2 (fr) 2004-10-29 2005-10-28 Preparations pharmaceutiques pour traiter les consequences de l'abus d'alcool, de l'hepatite, de la pancreatite, de la maladie d'alzheimer, de la maladie de parkinson, du diabete, des maladies renales toxiques, des dommages de reperfusions, de l'arteriosclerose et leurs utilisations en tant qu'antidote contre les poisons et

Publications (1)

Publication Number Publication Date
NO20072712L true NO20072712L (no) 2007-07-18

Family

ID=35695745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072712A NO20072712L (no) 2004-10-29 2007-05-29 Farmasoytisk preparat for behandling av konsekvensene av alkoholmisbruk, hepatitt, pankreatitt, Alzheimer's sykdom, Parkinsons sykdom, toksisk nyresykdom, reperfusjonsskade, arteriosklerose og som en antidote mot miljotoksiner og medikamentforgiftning

Country Status (8)

Country Link
US (1) US20090036400A1 (fr)
EP (1) EP1814533A2 (fr)
KR (1) KR20070085496A (fr)
AU (1) AU2005299148A1 (fr)
DE (2) DE102004052697A1 (fr)
NO (1) NO20072712L (fr)
RU (1) RU2007119712A (fr)
WO (1) WO2006045298A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006019906A1 (de) * 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung
DE102006019907A1 (de) * 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung
RU2354390C2 (ru) * 2007-05-15 2009-05-10 ГУ Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской академии медицинских наук ГУ НИИ фармакологии ТНЦ СО РАМН Осмотический диуретик, обладающий антитоксическим действием при отравлении алифатическими спиртами
RU2418580C1 (ru) * 2009-12-29 2011-05-20 Михаил Григорьевич Воронков Цинксодержащий антидот отравления этанолом и способ лечения с его использованием
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
ES2860823T3 (es) * 2014-12-09 2021-10-05 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS591415A (ja) * 1982-06-28 1984-01-06 Mochida Pharmaceut Co Ltd 循環系疾患治療剤
FR2674748B1 (fr) * 1991-04-03 1995-01-13 Oreal Utilisation de sphingolipides dans la preparation d'une composition cosmetique ou dermopharmaceutique protegeant la peau et les cheveux contre les effets nocifs de la pollution atmospherique.
EP0567653A4 (en) * 1991-11-14 1994-06-01 Sagami Chem Res Drug for hepatic diseases
CA2286442A1 (fr) * 1999-10-15 2001-04-15 Universite De Montreal Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie
MXPA03000772A (es) * 2000-08-01 2003-06-04 Pharmacia Corp Derivados de acido hexahidro-7-1h-azepin-2-il-hexanoico como inhibidores de oxido nitrico sintasa inducible.
ES2297176T5 (es) * 2002-02-12 2011-12-07 HUNZA DI PISTOLESI ELVIRA & C. S.A.S. Composiciones que contienen n-acil-fosfatidil-etanolaminas y/o mezclas de n-acil-etanolaminas con ácidos fosfatídicos o ácidos lisofosfatídicos.
EP1585508B1 (fr) * 2003-01-20 2009-04-01 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Utilisation de sphingolipides pour reduire les taux de triacylglycerol et de cholesterol dans le plasma
GB0301395D0 (en) * 2003-01-21 2003-02-19 Univ Aston Inflammatory disorder treatment

Also Published As

Publication number Publication date
US20090036400A1 (en) 2009-02-05
EP1814533A2 (fr) 2007-08-08
RU2007119712A (ru) 2008-12-10
AU2005299148A1 (en) 2006-05-04
DE102004052697A1 (de) 2006-05-04
WO2006045298A3 (fr) 2007-05-10
KR20070085496A (ko) 2007-08-27
WO2006045298A2 (fr) 2006-05-04
DE112005003310A5 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
NO20072712L (no) Farmasoytisk preparat for behandling av konsekvensene av alkoholmisbruk, hepatitt, pankreatitt, Alzheimer's sykdom, Parkinsons sykdom, toksisk nyresykdom, reperfusjonsskade, arteriosklerose og som en antidote mot miljotoksiner og medikamentforgiftning
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
ES2774267T3 (es) Compuestos inhibidores de metaloenzimas
JP2023533447A5 (fr)
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
WO2008061795A3 (fr) Nouveaux composés destinés au traitement de maladies associés à des protéines amyloïdes ou de type amyloïde
US20190077793A1 (en) Bisamide sarcomere activating compounds and uses thereof
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BR0308784A (pt) Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos
WO2004085433A3 (fr) Modulateurs allosteriques positifs du recepteur nicotinique de l'acetylcholine
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
MY146407A (en) A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
WO2008023258A8 (fr) Dérivés de pipéridine
WO2010067078A3 (fr) Sels de xanthylium disubstitués en 3 et 6
MX2010004176A (es) Derivado de triazol 1,3,5-trisustituido.
WO2008080988A3 (fr) Dérivées de cyclopentanone, leur méthode de synthèse et leurs utilisations
US20200270214A1 (en) NADPH Oxidase Inhibitors and Uses Thereof
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
DK2032534T3 (da) 4-[(3-fluorphenoxy)phenylmethyl]piperidinmethansulfonat: anvendelser, fremgangsmåder til syntese og farmaceutiske præparater
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
WO2007145589A8 (fr) Peptides capables de se lier à un peptide bêta-amyloïde
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
WO2008036316A3 (fr) Inhibiteurs pipéridines et pyrrolidines de la bêta-secrétase utilisés dans le traitement de la maladie d'alzheimer
BRPI0915627A8 (pt) Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application